

Supplementary Material

1 Supplementary Tables

Table S1. Differences by type of advanced therapy (gene therapies versus cell and tissue therapies)

Design and methodology of the pivotal trial	Gene Therapies	Non-Genes Therapies
Mean (SD) number of pivotal clinical trials	1,27 (0,65)	1,14 (0,38)
Phase of the trials		
Phase 1, Phase 1/2, Phase 2 and retrospective trials	7	3
Phase 2/3 and Phase 3 ¹	7	6
Type of control		
Non-controlled ²	13	3
Placebo or active controlled	1	6
Randomisation		
Yes	2	6
No	12	3
Blinding design		
Open	14	7
Single or double	0	2
Blinding evaluation		
Yes	2	7
No	12	2
Multicentre		
Yes	11	9
No	3	0
Number of arms		
1 arm	11	2
≥ 2 arms	3	7
Design		
Parallel	2	6
Other ³	12	3
Type of objective		
Superiority and non-inferiority	1	6
Other	13	3
Main outcome		
Final variable	2	3
Intermediate variable	12	6
Type of primary variable		
Number of quantitative variables	13	4
Number of qualitative variables	2	5
Health-related quality of life variables		
Yes	9	7
No	7	3

Sample size (n=17): Gene therapies (n= 10), non-gene therapies (n=7). Non-gene therapies comprise both cell and tissue engineered medicinal products. ¹ Including 1 retrospective study; ² Including historical controls and "other" studies; ³ Including single, crossover and "other" studies. SD: standard deviation.